These treatments target tissue quality and tissue biology rather than structural volume. Biostimulators stimulate collagen production over time; polynucleotides support cellular repair and tissue signalling; PRP and selected regenerative preparations work through growth-factor-mediated pathways. Each is distinct in mechanism and is not interchangeable with the others or with conventional injectables.
Treatment planning begins with assessment of tissue condition, treatment history, and overall goals. Not every patient requires biostimulatory or regenerative treatment — and for some, a better starting point may be medical skincare, conventional injectables, or a surgical plan. Where these treatments are indicated, they are planned as part of a broader clinical approach rather than as isolated interventions.
Treatment pathways — selected by indication
Selected biostimulatory injectables — including CaHA, PLLA, and PDLLA formulations — are used where longer-term tissue support and collagen stimulation are part of the clinical indication. The mechanism is distinct from dermal filler: the aim is not immediate filler-style volume, but structural remodelling and tissue quality improvement over time. Product choice, placement depth, and timing are determined by tissue condition, treatment history, and the broader facial plan.
Polynucleotides (PN) support tissue repair and skin quality through a nucleotide-based mechanism distinct from both filler and biostimulatory injectables. They are used selectively where skin quality, tissue response, or cellular repair support is part of the treatment goal — not as a routine skin booster equivalent. Indication and timing are assessed within the broader clinical plan.
Platelet-rich plasma (PRP) may be used where autologous growth-factor support is part of the treatment goal — including as an adjunct within a broader regenerative or skin-quality plan. Where clinically relevant, selected additional regenerative preparations may be considered. These are not standalone aesthetic treatments; indication, method, and timing are determined within the overall clinical plan and are not applied routinely.
Not every ageing or skin-quality concern is best addressed through biostimulatory or regenerative treatment. Where structural change, volume loss, or dynamic lines are dominant, conventional injectables or surgical planning may be more appropriate. The role of these treatments is specific — and where they are not the right fit, treatment planning will reflect that.
Treatment is selected after assessment of tissue condition, skin quality, treatment history, and overall goals. Candidacy is not assumed — some patients may be better served by medical skincare, conventional injectables, or a surgical approach at this stage. Where biostimulatory or regenerative treatment is indicated, the method, product, and timing are determined within the broader plan.
The consultation determines which of these applies.